JP2016500660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500660A5 JP2016500660A5 JP2015534747A JP2015534747A JP2016500660A5 JP 2016500660 A5 JP2016500660 A5 JP 2016500660A5 JP 2015534747 A JP2015534747 A JP 2015534747A JP 2015534747 A JP2015534747 A JP 2015534747A JP 2016500660 A5 JP2016500660 A5 JP 2016500660A5
- Authority
- JP
- Japan
- Prior art keywords
- capromorelin
- composition
- companion animal
- oral
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 claims 47
- 229950004826 capromorelin Drugs 0.000 claims 47
- 239000000203 mixture Substances 0.000 claims 27
- 241001465754 Metazoa Species 0.000 claims 26
- 238000000034 method Methods 0.000 claims 25
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 17
- 230000037396 body weight Effects 0.000 claims 12
- 235000003599 food sweetener Nutrition 0.000 claims 9
- 239000003765 sweetening agent Substances 0.000 claims 9
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 208000022531 anorexia Diseases 0.000 claims 6
- 206010061428 decreased appetite Diseases 0.000 claims 6
- 239000001329 FEMA 3811 Substances 0.000 claims 5
- 239000001512 FEMA 4601 Substances 0.000 claims 5
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims 5
- 239000005913 Maltodextrin Substances 0.000 claims 5
- 229920002774 Maltodextrin Polymers 0.000 claims 5
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims 5
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 claims 5
- 239000004376 Sucralose Substances 0.000 claims 5
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 claims 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims 5
- 239000001685 glycyrrhizic acid Substances 0.000 claims 5
- 229960004949 glycyrrhizic acid Drugs 0.000 claims 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims 5
- 235000019410 glycyrrhizin Nutrition 0.000 claims 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 5
- 229940035034 maltodextrin Drugs 0.000 claims 5
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 claims 5
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 claims 5
- 235000010434 neohesperidine DC Nutrition 0.000 claims 5
- 235000019203 rebaudioside A Nutrition 0.000 claims 5
- 235000019408 sucralose Nutrition 0.000 claims 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 5
- 239000000892 thaumatin Substances 0.000 claims 5
- 235000010436 thaumatin Nutrition 0.000 claims 5
- 235000009499 Vanilla fragrans Nutrition 0.000 claims 4
- 244000263375 Vanilla tahitensis Species 0.000 claims 4
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims 4
- 235000013305 food Nutrition 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 4
- 230000004580 weight loss Effects 0.000 claims 4
- 244000228451 Stevia rebaudiana Species 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 244000144972 livestock Species 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 241000202807 Glycyrrhiza Species 0.000 claims 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 239000004384 Neotame Substances 0.000 claims 2
- 239000004383 Steviol glycoside Substances 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 239000000905 isomalt Substances 0.000 claims 2
- 235000010439 isomalt Nutrition 0.000 claims 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 2
- 229940010454 licorice Drugs 0.000 claims 2
- 239000000845 maltitol Substances 0.000 claims 2
- 235000010449 maltitol Nutrition 0.000 claims 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 2
- 229940035436 maltitol Drugs 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 235000019412 neotame Nutrition 0.000 claims 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims 2
- 108010070257 neotame Proteins 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 235000010356 sorbitol Nutrition 0.000 claims 2
- 235000019411 steviol glycoside Nutrition 0.000 claims 2
- 229930182488 steviol glycoside Natural products 0.000 claims 2
- 150000008144 steviol glycosides Chemical class 0.000 claims 2
- 235000019202 steviosides Nutrition 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000002562 thickening agent Substances 0.000 claims 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940085605 saccharin sodium Drugs 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706164P | 2012-09-27 | 2012-09-27 | |
| US61/706,164 | 2012-09-27 | ||
| PCT/US2013/062227 WO2014052780A2 (en) | 2012-09-27 | 2013-09-27 | Compositions and methods of use of an inappetance-controlling compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041063A Division JP6796097B2 (ja) | 2012-09-27 | 2018-03-07 | 食欲不振制御化合物の組成物および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500660A JP2016500660A (ja) | 2016-01-14 |
| JP2016500660A5 true JP2016500660A5 (https=) | 2016-11-10 |
| JP6779618B2 JP6779618B2 (ja) | 2020-11-04 |
Family
ID=50339468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534747A Active JP6779618B2 (ja) | 2012-09-27 | 2013-09-27 | 食欲不振制御化合物の組成物および使用方法 |
| JP2018041063A Active JP6796097B2 (ja) | 2012-09-27 | 2018-03-07 | 食欲不振制御化合物の組成物および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041063A Active JP6796097B2 (ja) | 2012-09-27 | 2018-03-07 | 食欲不振制御化合物の組成物および使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11090292B2 (https=) |
| EP (3) | EP3524260B1 (https=) |
| JP (2) | JP6779618B2 (https=) |
| KR (6) | KR20250048114A (https=) |
| CN (2) | CN111419845A (https=) |
| AR (2) | AR092713A1 (https=) |
| AU (2) | AU2013323349B2 (https=) |
| BR (1) | BR112015006282B1 (https=) |
| CA (1) | CA2886091C (https=) |
| DK (1) | DK3524260T3 (https=) |
| ES (1) | ES2959427T3 (https=) |
| MX (2) | MX2015003564A (https=) |
| NZ (2) | NZ746394A (https=) |
| PL (1) | PL3524260T3 (https=) |
| PT (1) | PT3524260T (https=) |
| RU (1) | RU2648958C2 (https=) |
| TW (3) | TWI732158B (https=) |
| WO (1) | WO2014052780A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10975070B2 (en) | 2010-02-26 | 2021-04-13 | Raqualia Pharma Inc. | Ghrelin receptor agonist for treatment of cachexia |
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| BR112015006282B1 (pt) | 2012-09-27 | 2021-11-23 | Aratana Therapeutics, Inc | Composições e usos de capromorelina para controle de inapetência |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US9700591B2 (en) * | 2015-01-28 | 2017-07-11 | Aratana Therapeutics, Inc. | Compositions and methods for chronic use of a weight-gaining compound |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| WO2018089723A1 (en) * | 2016-11-11 | 2018-05-17 | Hill's Pet Nutrition, Inc. | Compositions and methods of pet food |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US193273A (en) * | 1877-07-17 | Improvement in material for pulley-covers | ||
| JP2893901B2 (ja) * | 1990-09-07 | 1999-05-24 | 株式会社岐阜免疫研究所 | 動物用抗体含有油性ペースト製剤 |
| CA2095786A1 (en) * | 1992-05-08 | 1993-11-09 | Franco J. Vaccarino | Method of stimulating appetite |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| DE60140285D1 (de) | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
| EP1181933A3 (en) * | 2000-06-29 | 2002-04-10 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating or increasing appetite |
| US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| JP2007532495A (ja) * | 2004-04-07 | 2007-11-15 | ガストロテック・ファルマ・アクティーゼルスカブ | グレリン欠乏を治療するための分泌促進薬の使用 |
| WO2006045313A2 (en) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Uses of secretagogues for treatment of organ transplant patients |
| US8226973B2 (en) * | 2005-11-02 | 2012-07-24 | Nestec, S. A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
| NZ571183A (en) * | 2006-03-13 | 2010-09-30 | Liat Mintz | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation |
| US8299022B2 (en) | 2006-09-27 | 2012-10-30 | Ipsen Pharma S.A.S. | Analogs of ghrelin substituted at the N-terminal |
| JP2008127377A (ja) * | 2006-11-24 | 2008-06-05 | Jichi Medical Univ | Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。 |
| US20080226802A1 (en) * | 2007-03-14 | 2008-09-18 | Concentrate Manufacturing Company Of Ireland | Beverage having natural sweeteners with one or more stevia components and source of berry |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| RU2007129408A (ru) * | 2007-07-31 | 2009-02-10 | Игорь Николаевич Жирков (RU) | Способ выращивания поросят в период откорма |
| FR2920295B1 (fr) | 2007-09-05 | 2009-12-11 | Desvac | Dispositif d'injection de produits veterinaires a des volailles, comprenant un element de contention presentant une forme anatomique incluant des moyens de calage d'un os reperable |
| CN101854814B (zh) * | 2007-11-12 | 2013-07-31 | 三荣源有限公司 | 改善甜叶菊提取物甜味的方法 |
| EP2412713B1 (en) * | 2009-03-26 | 2016-11-30 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| US10975070B2 (en) | 2010-02-26 | 2021-04-13 | Raqualia Pharma Inc. | Ghrelin receptor agonist for treatment of cachexia |
| BR112015006282B1 (pt) | 2012-09-27 | 2021-11-23 | Aratana Therapeutics, Inc | Composições e usos de capromorelina para controle de inapetência |
-
2013
- 2013-09-27 BR BR112015006282-2A patent/BR112015006282B1/pt active IP Right Grant
- 2013-09-27 EP EP19161662.2A patent/EP3524260B1/en active Active
- 2013-09-27 EP EP13841455.2A patent/EP2906041A4/en not_active Withdrawn
- 2013-09-27 TW TW107142255A patent/TWI732158B/zh active
- 2013-09-27 NZ NZ746394A patent/NZ746394A/en unknown
- 2013-09-27 JP JP2015534747A patent/JP6779618B2/ja active Active
- 2013-09-27 RU RU2015114996A patent/RU2648958C2/ru active
- 2013-09-27 PT PT191616622T patent/PT3524260T/pt unknown
- 2013-09-27 KR KR1020257009208A patent/KR20250048114A/ko active Pending
- 2013-09-27 ES ES19161662T patent/ES2959427T3/es active Active
- 2013-09-27 TW TW109121986A patent/TW202106298A/zh unknown
- 2013-09-27 TW TW102135177A patent/TWI667024B/zh active
- 2013-09-27 KR KR1020217042990A patent/KR20220003640A/ko not_active Ceased
- 2013-09-27 AR ARP130103486A patent/AR092713A1/es not_active Application Discontinuation
- 2013-09-27 KR KR1020217001509A patent/KR20210009438A/ko not_active Ceased
- 2013-09-27 CA CA2886091A patent/CA2886091C/en active Active
- 2013-09-27 DK DK19161662.2T patent/DK3524260T3/da active
- 2013-09-27 WO PCT/US2013/062227 patent/WO2014052780A2/en not_active Ceased
- 2013-09-27 AU AU2013323349A patent/AU2013323349B2/en active Active
- 2013-09-27 NZ NZ707174A patent/NZ707174A/en active IP Right Revival
- 2013-09-27 PL PL19161662.2T patent/PL3524260T3/pl unknown
- 2013-09-27 CN CN202010001164.1A patent/CN111419845A/zh active Pending
- 2013-09-27 US US14/039,114 patent/US11090292B2/en active Active
- 2013-09-27 MX MX2015003564A patent/MX2015003564A/es active IP Right Grant
- 2013-09-27 KR KR1020157009647A patent/KR20150058345A/ko not_active Ceased
- 2013-09-27 KR KR1020197037811A patent/KR20190143484A/ko not_active Ceased
- 2013-09-27 CN CN201380061931.6A patent/CN105072909A/zh active Pending
- 2013-09-27 EP EP23191187.6A patent/EP4302825A3/en active Pending
- 2013-09-27 KR KR1020237019962A patent/KR20230097201A/ko not_active Ceased
-
2015
- 2015-03-19 MX MX2022015141A patent/MX2022015141A/es unknown
-
2016
- 2016-08-22 AU AU2016216741A patent/AU2016216741B2/en active Active
-
2018
- 2018-03-07 JP JP2018041063A patent/JP6796097B2/ja active Active
-
2021
- 2021-10-22 AR ARP210102942A patent/AR123902A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500660A5 (https=) | ||
| Krautwald-Junghanns et al. | Aspergillosis in birds: an overview of treatment options and regimens | |
| RU2015114996A (ru) | Композиции и способы применения соединения для борьбы с отсутствием аппетита | |
| US8722115B2 (en) | Methods for improving health in animals | |
| HRP20180774T1 (hr) | Orodisperzibilni dezmopresin za povećanje početnog razdoblja sna neometanog s nokturijom | |
| US10117890B2 (en) | Methods and compositions for treating pain | |
| JP2017534613A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| US20240285576A1 (en) | R-mdma for treatment of pain | |
| SI2906213T1 (en) | Veterinary method for easing noise sensitivity | |
| JP2016525548A5 (https=) | ||
| MX2008013873A (es) | Formulacion de medicamento liquida. | |
| CN103751201A (zh) | 一种犬、猫用抗寄生虫口服崩解片及其制备方法 | |
| Söderman et al. | Activation of nicotinic α7 acetylcholine receptor enhances long term potentation in wild type mice but not in APPswe/PS1ΔE9 mice | |
| JP2013542737A (ja) | 昆虫侵入を阻害するための方法 | |
| US20150320783A1 (en) | N-methylserotonin and related substances for use in treating / lessening the occurrence of hot flashes related to menopause | |
| CN101129188B (zh) | 一种水飞蓟素咀嚼片及其制备方法 | |
| EP3366288B1 (en) | Lithium ascorbate exhibiting anti-stress, anxiolytic and anti-depression activity | |
| JP6914256B2 (ja) | 膵臓脂肪浸潤を予防または治療し、膵臓脂肪浸潤に起因する膵臓病変、糖尿病または他の関連症状を緩和するための組成物、および方法 | |
| KR101783306B1 (ko) | ＰＤＫｓ 억제제를 유효성분으로 함유하는 알러지성 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2017513866A5 (https=) | ||
| JP6676329B2 (ja) | 口腔粘膜投与用の唾液分泌促進用医薬組成物 | |
| US20100227891A1 (en) | Threshold blood omeprazole concentration is 50 ng/ml for the maintenance of intragastric ph of at least 4.0 after oral dosing with cma-omeprazole, agn 201904-z | |
| JP7181695B2 (ja) | 抗認知症剤及び短期記憶障害改善／抑制剤 | |
| CN121974841A (en) | Compounds for treating liver cancer | |
| Griffiths et al. | Prolonged chemical restraint of walrus (Odobenus rosmarus) with etorphine supplemented with medetomidine |